Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes.
10.3904/kjim.2011.26.2.153
- Author:
Jinwoo LEE
1
;
Chang Hoon LEE
;
Deog Kyeom KIM
;
Ho Il YOON
;
Jae Yeol KIM
;
Sang Min LEE
;
Seok Chul YANG
;
Jae Ho LEE
;
Chul Gyu YOO
;
Choon Taek LEE
;
Hee Soon CHUNG
;
Young Whan KIM
;
Sung Koo HAN
;
Jae Joon YIM
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea. yimjj@snu.ac.kr
- Publication Type:Original Article ; Comparative Study
- Keywords:
Levofloxacin;
Moxifloxacin;
Tuberculosis, multidrug-resistant;
Quinolones;
Tuberculosis
- MeSH:
Adult;
Antitubercular Agents/adverse effects/*therapeutic use;
Aza Compounds/adverse effects/*therapeutic use;
Case-Control Studies;
Chi-Square Distribution;
*Drug Resistance, Multiple, Bacterial;
Drug Therapy, Combination;
Extensively Drug-Resistant Tuberculosis/*drug therapy/microbiology/mortality;
Female;
Humans;
Logistic Models;
Male;
Middle Aged;
Mycobacterium tuberculosis/*drug effects/pathogenicity;
Odds Ratio;
Ofloxacin/adverse effects/*therapeutic use;
Quinolines/adverse effects/*therapeutic use;
Recurrence;
Remission Induction;
Republic of Korea;
Retrospective Studies;
Risk Assessment;
Risk Factors;
Time Factors;
Treatment Outcome;
Tuberculosis, Multidrug-Resistant/*drug therapy/microbiology/mortality
- From:The Korean Journal of Internal Medicine
2011;26(2):153-159
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). METHODS: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). RESULTS: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). CONCLUSIONS: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.
